Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Novartis' Fabhalta (iptacopan) receives FDA traditional approval to slow kidney function decline in primary immunoglobulin A nephropathy
Small molecule, autoimmune, complement inhibitor, IgA nephropathy, kidney disease - Read more

Dimerix acquires Mission Therapeutics' phase 2-ready AKI candidate MTX652, $5M upfront, $292M deal
Acquisition, rare disease, small molecule, milestone payments, nephrology - Read more

Aqemia, Sanofi expand multi-year AI drug discovery collaboration, up to $140M in payments
Research collaboration, small molecule, AI/ML, drug discovery, milestone payments - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Insmed's (treprostinil palmitil inhalation powder) shows 12-month durability in pulmonary arterial hypertension open-label extension study
Small molecule, cardiovascular, inhaled prostanoid, pulmonary arterial hypertension, treprostinil, NT-proBNP - Read more

Takeda's (zasocitinib) clears scalp psoriasis in 75% of patients in Ph3 moderate-to-severe plaque psoriasis trials
Small molecule, autoimmune, TYK2 inhibitor, psoriasis, IL-23 pathway - Read more

Kalaris Therapeutics reports positive Ph1 results for TH103 (TH103) targeting anti-VEGF in neovascular age-related macular degeneration
Antibody, eye disease, monoclonal antibody, neovascular age-related macular degeneration, anti-VEGF, intraocular retention - Read more

Biomed Industries presents positive Ph2/3 results for Bionetide (NA-921) targeting MECP2-related Rett syndrome
Small molecule, neurological, Rett syndrome, MECP2 mutation, oral therapy, rare disease - Read more

Trellis Bioscience raises $9M Series C to advance calpurbatug Phase 2 trial for prosthetic joint infections
Infectious disease, antibody, clinical-stage, antimicrobial resistance, biofilm - Read more

Juno Bio raises $3.8M in funding to expand clinical testing and microbiome diagnostic infrastructure
Microbiome, diagnostics, next-generation sequencing, women's health, multi-omics - Read more

REGENXBIO prices ~$100M public offering of common stock and pre-funded warrants
Gene therapy, AAV, rare disease, clinical-stage - Read more

BCG, HealthKois report: India's life sciences sector at innovation turning point, urging scale-up
Life sciences innovation, rare disease, strategic, financial - Read more

Jasper Therapeutics merges with Kira Pharmaceuticals, gaining differentiated complement portfolio including dual-inhibitor KP-104
Monoclonal antibody, rare disease, autoimmune, strategic, major transaction - Read more

U.S. Senate bill targets foreign pharmaceutical supply chain transparency, focusing on China's drug ingredient dominance
Small molecule, infectious disease, supply chain, legislative - Read more

Creative Biolabs launches multi-platform solutions to study brain-immune-gut axis regulation mechanisms
In vitro research platform, neurological, neuroimmunology, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

GSK discontinues (camlipixant) P2X3 antagonist development for refractory chronic cough after Ph3 failure
Small molecule, respiratory, P2X3 antagonist, refractory chronic cough, irritable bowel syndrome - Read more

ASHP reports 227 active U.S. drug shortages in Q2 2026, with chemotherapies hit hardest
Drug shortages, oncology, operational, supply chain - Read more

Novo Nordisk, Alvotech face FDA Form 483 citations over manufacturing deficiencies at separate facilities
Biologics manufacturing, biosimilar, operational, regulatory - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here